<?xml version='1.0' encoding='utf-8'?>
<document id="18644960"><sentence text="Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model."><entity charOffset="42-50" id="DDI-PubMed.18644960.s1.e0" text="rifampin" /></sentence><sentence text="New drugs are needed to shorten the duration of tuberculosis treatment" /><sentence text=" R207910, a diarylquinoline, is very active against Mycobacterium tuberculosis both in vitro and in mice"><entity charOffset="12-27" id="DDI-PubMed.18644960.s3.e0" text="diarylquinoline" /></sentence><sentence text=" In healthy volunteers, the coadministration of R207910 and rifampin induced the increased metabolism of R207910, resulting in a 50% reduction in the level of R207910 exposure"><entity charOffset="60-68" id="DDI-PubMed.18644960.s4.e0" text="rifampin" /></sentence><sentence text=" We assessed the impact of reducing the dose of R207910 on its efficacy when R207910 was combined with a background regimen of isoniazid, rifampin, and pyrazinamide"><entity charOffset="127-136" id="DDI-PubMed.18644960.s5.e0" text="isoniazid" /><entity charOffset="138-146" id="DDI-PubMed.18644960.s5.e1" text="rifampin" /><entity charOffset="152-164" id="DDI-PubMed.18644960.s5.e2" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.18644960.s5.e0" e2="DDI-PubMed.18644960.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18644960.s5.e0" e2="DDI-PubMed.18644960.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18644960.s5.e0" e2="DDI-PubMed.18644960.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18644960.s5.e1" e2="DDI-PubMed.18644960.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18644960.s5.e1" e2="DDI-PubMed.18644960.s5.e2" /></sentence><sentence text=" Addition of 25 mg/kg of body weight or 12" /><sentence text="5 mg/kg R207910 to the background regimen resulted in faster bacterial clearance and culture negativity" /><sentence text=" The difference in efficacy between the two doses was not statistically significant" /><sentence text=" The minimal bactericidal dose of R207910 when it was tested as part of the combination was identical to that when it was tested as monotherapy" /><sentence text=" Because of the drug-drug interaction in humans, the activity of R207910 in humans could be less than that expected from studies with mice" /><sentence text=" Our data from the mouse model demonstrate that R207910 has significant activity, even when its exposure is reduced by 50% and when it is added to a strong background regimen of isoniazid, rifampin, and pyrazinamide"><entity charOffset="178-187" id="DDI-PubMed.18644960.s11.e0" text="isoniazid" /><entity charOffset="189-197" id="DDI-PubMed.18644960.s11.e1" text="rifampin" /><entity charOffset="203-215" id="DDI-PubMed.18644960.s11.e2" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.18644960.s11.e0" e2="DDI-PubMed.18644960.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18644960.s11.e0" e2="DDI-PubMed.18644960.s11.e1" /><pair ddi="false" e1="DDI-PubMed.18644960.s11.e0" e2="DDI-PubMed.18644960.s11.e2" /><pair ddi="false" e1="DDI-PubMed.18644960.s11.e1" e2="DDI-PubMed.18644960.s11.e1" /><pair ddi="false" e1="DDI-PubMed.18644960.s11.e1" e2="DDI-PubMed.18644960.s11.e2" /></sentence><sentence text=" In killing kinetic studies, the bactericidal effect of R207910 in mice was modest during the first week of treatment, but it increased in the following 3 weeks, while the bactericidal activity of isoniazid was limited to the first week of treatment"><entity charOffset="197-206" id="DDI-PubMed.18644960.s12.e0" text="isoniazid" /></sentence><sentence text="" /></document>